Levobupivacaine.

G. Ivani, B. Borghi, H. van Oven

Research output: Contribution to journalArticle

Abstract

Bupivacaine has been the most widely used local anaesthetic for years. Recent studies point out levobupivacaine, an S(-) isomer of the racemic bupivacaine. This review shows the properties of levobupivacaine describing the animal and human volunteers studies on toxicity and the first clinical studies in obstetrics, general surgery and paediatrics. In vitro animal studies show that, injected intravenously, levobupivacaine has less cardiotoxic effects and less toxic effects on the CNS in comparison with both R(+) bupivacaine and bupivacaine itself, caused by a minor affinity for brain tissue resulting in less CNS depressant effects as well as for myocardial tissue, which leads to a higher dose necessary before being lethal in comparison to bupivacaine. Studies in human volunteers confirm these results, adding a minor arrhythmogenic, and less negative inotropic effect. Clinical studies show no significant differences in onset, duration and sensory block, but complete regression of sensory block takes longer. Potency is equal for levo- and bupivacaine according to MLAC in labour analgesia. Studies in paediatrics confirm effective analgesia but show less intensity of motor block. The reduced toxicity of levobupivacaine gives wider safety margin in the daily clinical practice both for single shot and for continuous infusion, intraoperatively during various surgical procedures and for the postoperative pain control and analgesia in labour.

Original languageEnglish
Pages (from-to)20-23
Number of pages4
JournalMinerva Anestesiologica
Volume67
Issue number9 Suppl 1
Publication statusPublished - Sep 2001

Fingerprint

Bupivacaine
Analgesia
Volunteers
Obstetric Surgical Procedures
Central Nervous System Depressants
Pediatrics
Poisons
Postoperative Pain
Local Anesthetics
levobupivacaine
Safety
Brain

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Ivani, G., Borghi, B., & van Oven, H. (2001). Levobupivacaine. Minerva Anestesiologica, 67(9 Suppl 1), 20-23.

Levobupivacaine. / Ivani, G.; Borghi, B.; van Oven, H.

In: Minerva Anestesiologica, Vol. 67, No. 9 Suppl 1, 09.2001, p. 20-23.

Research output: Contribution to journalArticle

Ivani, G, Borghi, B & van Oven, H 2001, 'Levobupivacaine.', Minerva Anestesiologica, vol. 67, no. 9 Suppl 1, pp. 20-23.
Ivani G, Borghi B, van Oven H. Levobupivacaine. Minerva Anestesiologica. 2001 Sep;67(9 Suppl 1):20-23.
Ivani, G. ; Borghi, B. ; van Oven, H. / Levobupivacaine. In: Minerva Anestesiologica. 2001 ; Vol. 67, No. 9 Suppl 1. pp. 20-23.
@article{b8d964e113f54d8dbae67dda934ccf63,
title = "Levobupivacaine.",
abstract = "Bupivacaine has been the most widely used local anaesthetic for years. Recent studies point out levobupivacaine, an S(-) isomer of the racemic bupivacaine. This review shows the properties of levobupivacaine describing the animal and human volunteers studies on toxicity and the first clinical studies in obstetrics, general surgery and paediatrics. In vitro animal studies show that, injected intravenously, levobupivacaine has less cardiotoxic effects and less toxic effects on the CNS in comparison with both R(+) bupivacaine and bupivacaine itself, caused by a minor affinity for brain tissue resulting in less CNS depressant effects as well as for myocardial tissue, which leads to a higher dose necessary before being lethal in comparison to bupivacaine. Studies in human volunteers confirm these results, adding a minor arrhythmogenic, and less negative inotropic effect. Clinical studies show no significant differences in onset, duration and sensory block, but complete regression of sensory block takes longer. Potency is equal for levo- and bupivacaine according to MLAC in labour analgesia. Studies in paediatrics confirm effective analgesia but show less intensity of motor block. The reduced toxicity of levobupivacaine gives wider safety margin in the daily clinical practice both for single shot and for continuous infusion, intraoperatively during various surgical procedures and for the postoperative pain control and analgesia in labour.",
author = "G. Ivani and B. Borghi and {van Oven}, H.",
year = "2001",
month = "9",
language = "English",
volume = "67",
pages = "20--23",
journal = "Minerva Anestesiologica",
issn = "0375-9393",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "9 Suppl 1",

}

TY - JOUR

T1 - Levobupivacaine.

AU - Ivani, G.

AU - Borghi, B.

AU - van Oven, H.

PY - 2001/9

Y1 - 2001/9

N2 - Bupivacaine has been the most widely used local anaesthetic for years. Recent studies point out levobupivacaine, an S(-) isomer of the racemic bupivacaine. This review shows the properties of levobupivacaine describing the animal and human volunteers studies on toxicity and the first clinical studies in obstetrics, general surgery and paediatrics. In vitro animal studies show that, injected intravenously, levobupivacaine has less cardiotoxic effects and less toxic effects on the CNS in comparison with both R(+) bupivacaine and bupivacaine itself, caused by a minor affinity for brain tissue resulting in less CNS depressant effects as well as for myocardial tissue, which leads to a higher dose necessary before being lethal in comparison to bupivacaine. Studies in human volunteers confirm these results, adding a minor arrhythmogenic, and less negative inotropic effect. Clinical studies show no significant differences in onset, duration and sensory block, but complete regression of sensory block takes longer. Potency is equal for levo- and bupivacaine according to MLAC in labour analgesia. Studies in paediatrics confirm effective analgesia but show less intensity of motor block. The reduced toxicity of levobupivacaine gives wider safety margin in the daily clinical practice both for single shot and for continuous infusion, intraoperatively during various surgical procedures and for the postoperative pain control and analgesia in labour.

AB - Bupivacaine has been the most widely used local anaesthetic for years. Recent studies point out levobupivacaine, an S(-) isomer of the racemic bupivacaine. This review shows the properties of levobupivacaine describing the animal and human volunteers studies on toxicity and the first clinical studies in obstetrics, general surgery and paediatrics. In vitro animal studies show that, injected intravenously, levobupivacaine has less cardiotoxic effects and less toxic effects on the CNS in comparison with both R(+) bupivacaine and bupivacaine itself, caused by a minor affinity for brain tissue resulting in less CNS depressant effects as well as for myocardial tissue, which leads to a higher dose necessary before being lethal in comparison to bupivacaine. Studies in human volunteers confirm these results, adding a minor arrhythmogenic, and less negative inotropic effect. Clinical studies show no significant differences in onset, duration and sensory block, but complete regression of sensory block takes longer. Potency is equal for levo- and bupivacaine according to MLAC in labour analgesia. Studies in paediatrics confirm effective analgesia but show less intensity of motor block. The reduced toxicity of levobupivacaine gives wider safety margin in the daily clinical practice both for single shot and for continuous infusion, intraoperatively during various surgical procedures and for the postoperative pain control and analgesia in labour.

UR - http://www.scopus.com/inward/record.url?scp=0035467870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035467870&partnerID=8YFLogxK

M3 - Article

C2 - 11778089

AN - SCOPUS:0035467870

VL - 67

SP - 20

EP - 23

JO - Minerva Anestesiologica

JF - Minerva Anestesiologica

SN - 0375-9393

IS - 9 Suppl 1

ER -